Close Menu

depression

The trials are part of the second phase of the Implementing Genomics in Practice program, which is slated to receive $42 million in funding over 5 years.

This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.

Noisy Signal

The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.

To understand the evolution of brain conditions and other traits, investigators plan to sequence human and pathogen DNA in thousands of samples from Europe.

The Washington Post reports on the use of genetic tests to guide antidepressant treatment.

Researchers used a genome-wide association study to identify seven loci associated with ASD and other conditions, along with five loci linked to ASD alone.

Two independent teams described potential roles for gut microbes, and the compounds they produce, in schizophrenia, depression, and mental quality of life.

The findings underscored links between depression and other conditions and suggested  a number of potential new targets for treatment with existing drugs.

Polygenic risk scores for depression, bipolar disorder, and schizophrenia are associated with depression in a general population cohort.

Using UK Biobank and 23andMe data, researchers found 352 loci influencing sleep time preferences, including sites near brain- and retina-expressed genes.

Pages

The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.

The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.

Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.

In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.